Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. easiviral

EASIVIRAL SIGNED

EASIVIRAL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 EASIVIRAL project word cloud

Explore the words cloud of the EASIVIRAL project. It provides you a very rough idea of what is the project "EASIVIRAL" about.

biomarkers    vl    viruses    partners    format    combo    patents    refrigerated    manufacturing    viral    portable    critical    local    september    portability    prescription    region    robustness    acceptance    excellence    cumulative    solution    grow    offers    decades    altratech    clinics    detection    feasibility    trl    battery    made    18m    simultaneous    patient    share    purify    biotechnologies    30    intervention    exceeded    hiv    therapy    pcr    life    successful    2015    capacity    crisis    commercialise    venture    diagnostics    clinical    significantly    ceo    labs    techniques    sme    point    easiviral    elimination    portfolio    structure    stops    granted    revenues    innovative    seal    1b    operated    gt    care    ebitda    phc    centered    jobs    virus    outcomes    market    disrupt    innovations    diagnoses    ltd    detect    competitiveness    urges    received    exists    reagents    alone    75    threshold    enhances    76    improvements    stated    displace    laboratories    people    12    poc    saving    see    time    2016    accuracy    hepatitis    capture    kit    load    spread    2024    proven    create    210m    blood    accelerated    disruptive    combination    mins    rt    supply   

Project "EASIVIRAL" data sheet

The following table provides information about the project.

Coordinator		 ALTRATECH LIMITED 

Organization address
address: 4TH FLOOR 103/104 O CONNELL STREET
city: LIMERICK
postcode: V94 AT85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.easiviral.com
 Total cost 2˙969˙000 €
 EC max contribution 2˙969˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALTRATECH LIMITED IE (LIMERICK) coordinator 2˙969˙000.00

Map

 Project objective

In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

 Deliverables

List of deliverables.
1000 fabricated silicon sensor chips Demonstrators, pilots, prototypes 2020-02-12 16:28:30
Poster showing lower-limit of quantification Websites, patent fillings, videos etc. 2020-02-12 16:28:31
Data Sheets, App Notes, White Papers, Publicity material Websites, patent fillings, videos etc. 2020-01-30 10:06:41

Take a look to the deliverables list in detail:  detailed list of EASIVIRAL deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIVIRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASIVIRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More